Moneycontrol
HomeNewsOpinionFocus on new products at pharma companies as generic Revlimid opportunity draws to a close

Focus on new products at pharma companies as generic Revlimid opportunity draws to a close

The current market restrictions that are powering generic Revlimid revenues will end in January 2026

Companies have several high value drugs in the pipeline

To read the full story,

Subscribe to Moneycontrol PRO
  • Ad-free Experience
  • Access Exclusive Stories
  • Weekly Investment Ideas
  • Daily Technical Calls

Are you a PRO subscriber? Sign In

What Do You Get

  • Ad free Experience

    Seamless navigation, faster responses.

  • Expert Perspective

    Explore 230+ exclusive editorials every month

  • +

    Uncover Insights from World-Renowned Experts and Journalists

  • Actionable Insights

    40+ weekly investment ideas + 3 to 4 daily technical calls

  • Virtual Events

    Exclusive Live Webinars for Expert Trading & Investment Strategies!

  • Newsletters

    Stay ahead with daily and weekly insights

Unlock exclusive discounts